Semaglutide for Alcohol Use Disorder

NCT05520775 · Completed

Last updated 2026-05-28

This clinical trial is testing whether the medication semaglutide can help reduce alcohol consumption in adults with alcohol use disorder, some of whom may also smoke cigarettes.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, triple-blind basic-science study

Participants 48 people

Who can join Ages 21–65 · all sexes Healthy volunteers accepted.

Timeline Started 2022-09 · est. completion 2024-04

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT05520775 ↗

Description as written by the study sponsor.

This is an early-Phase II human laboratory trial using a randomized, placebo-controlled, dose-ranging design to investigate the effects of semaglutide, a GLP-1 receptor agonist, on alcohol-related outcomes in adults with alcohol use disorder (AUD).

Treatments tested

Semaglutide Drug

Semaglutide (subcutaneous)
Sham/placebo Drug

Sham subcutaneous injection

Main thing measured	Change in Alcohol Consumed
Sponsor	University of North Carolina, Chapel Hill
Conditions studied	Alcohol Use Disorder, Cigarette Smoking
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05520775 ↗